Bighat Biosciences Completes Its Acquisition Of Frugi Biotechnology
03/28/22, 1:01 PM
Location
san mateoIndustry
biotechnology
other
BigHat Biosciences, Inc., a biotechnology company developing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced the acquisition of Frugi Biotechnology, a biotechnology company developing cost-effective and high-quality cell-free protein synthesis (CFPS) technology. The terms of the transaction were not disclosed.
Company Info
Location
1900 alameda de las pulgas
San Mateo, California, United States
Company info
Founded in 2019, BigHat Biosciences is a Series A biotechnology company in the San Francisco Bay Area. BigHat is led by a team of experts spanning machine learning, molecular biology, drug development, and medicine. BigHat is supported by a cadre of world leaders, including a Nobel Laureate and the physician-scientist that brought Herceptin to market. To date, BigHat has raised $25M from top investors led by a16z and 8VC and is quickly succeeding on partnerships with large biopharma partners. In addition to these collaborations, BigHat has active therapeutic programs spanning multiple domains of human health, including inflammation, oncology, hematology, and infectious diseases in preclinical studies.